Table 2.
Baseline characteristics of patients related to the second anti-TNF used.
| Variable | Whole cohort (N = 473) | Initially intravenous (IVi group) (N = 330) | Initially subcutaneous (SCi group) (N = 143) | p |
|---|---|---|---|---|
| Time from diagnosis to treatment (months), median (range) | 65 (1–444) | 76 (1–444) | 50 (1–382) | 0.05 |
| Concomitant IMM treatment (%) | 247 (52) | 168 (51) | 79 (55) | 0.42 |
| Partial Mayo score, median (range) | 5 (0–9) | 5 (0–9) | 6 (0–9) | 0.003 |
| Moderate/severe partial Mayo score (%) | 297 (65) | 202 (61) | 105 (74) | 0.01 |
| Moderate/severe endoscopic Mayo score (%) | 270 (87) | 281 (85) | 131 (92) | 0.01 |
Bold and italic characters within the Tables are used to highlight statistically significant results.